Investigational drug · Phase 2
BPM31510
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Glioblastoma, Glioblastoma Multiforme.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
11
Any phase or sponsor naming "BPM31510"
First trial start
2022
Aug 22, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BPM31510", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glioblastoma
- Glioblastoma Multiforme
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BPM31510" as an intervention, largest first.
- Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell CarcinomaPivotal-lookingCompleted
BPGbioIndustry
NCT00604890 · 186 participants · Start Mar 2008 · Primary completion Jan 2010
Drug: API 31510 3% Topical Cream; API 31510 1.5% Topical Cream · For: Superficial Basal Cell Carcinoma
Sites: Hot Springs, Arkansas; San Diego, California; Denver, Colorado · 11 sites in all
- BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid TumorsCompleted
BPGbioIndustry
NCT01957735 · 97 participants · Start Oct 2013 · Primary completion Feb 1, 2017
Drug: BP31510 monotherapy; BP31510 in combination with chemotherapy · For: Metastatic Cancer; Cancer; Solid Tumor
Sites: Sunnyvale, California; New York, New York; Houston, Texas
- A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)Active, not recruiting
BPGbioIndustry
NCT04752813 · 50 participants (planned) · Start Aug 22, 2022 · Primary completion Aug 25, 2026
Drug: BPM31510; Temozolomide (TMZ) · For: Glioblastoma; Glioblastoma Multiforme
Sites: Los Angeles, California; Palo Alto, California; Santa Barbara, California · 11 sites in all
- BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer PatientsCompleted
BPGbioIndustry
NCT02650804 · 45 participants · Start Jul 6, 2016 · Primary completion Jun 11, 2019
Drug: BPM31510 Nanosuspension Injection; Gemcitabine · For: Pancreatic Cancer
Sites: Gilbert, Arizona; Phoenix, Arizona; Gilroy, California · 12 sites in all
BPGbioIndustry
NCT00652080 · 35 participants · Start Jun 2008 · Primary completion Jan 2010
Drug: API 31510 · For: Squamous Cell Carcinoma
Sites: Hot Springs, Arkansas; San Diego, California; Buffalo Grove, Illinois · 5 sites in all
BPGbioIndustry
NCT03002935 · 25 participants · Start Jan 2017 · Primary completion Mar 2017
Drug: BPM31510 Oral Nanosuspension 4% · For: Healthy
Sites: Eatontown, New Jersey
BPGbioIndustry
NCT02486055 · 20 participants · Start Nov 2015 · Primary completion Jan 2016
Drug: BPM31510 Oral Nanosuspension 4% · For: Healthy
Sites: Eatontown, New Jersey
- BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With BevacizumabCompleted
Seema NagpalAcademic, hospital or other
NCT03020602 · 12 participants · Start Jan 4, 2017 · Primary completion Apr 4, 2019
Drug: Ubidecarenone Injectable Nanosuspension · For: Gliosarcoma; Recurrent Glioblastoma; Astrocytoma of Brain and 1 more
Sites: Palo Alto, California
Shasa HuAcademic, hospital or other
NCT02793960 · 11 participants · Start Aug 10, 2016 · Primary completion Aug 26, 2019
Drug: topical BPM31510 3.0% Cream · For: Epidermolysis Bullosa
Sites: Miami, Florida
- Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older Adults With SarcopeniaWithdrawn
AdventHealth Translational Research InstituteAcademic, hospital or other
NCT04999488 · 0 participants · Start Dec 2023 · Primary completion Dec 2024
Drug: BPM31510 · For: Sarcopenia
Sites: Orlando, Florida
Newest research
PubMed records naming it or its code names, newest first.
- BPM31510 Increases the CoQ Pool in Chemically Induced CoQ-Deficient Cells, CoQ-Deficient Patient Fibroblasts, and in Metabolically Active Murine Tissues.
Aristizabal-Henao JJ, Wessel SR, Stopka SA, et al. · FASEB J 2026
- Spatial mapping of CoQ10 repletion by BPM31510 in a genetic mouse model (Coq4F147C) of coenzyme Q deficiency.
Barriocanal-Casado E, Stopka SA, Pesini A, et al. · J Lipid Res 2026
- Elevated levels of mitochondrial CoQ10 induce ROS-mediated apoptosis in pancreatic cancer.
Dadali T, Diers AR, Kazerounian S, et al. · Sci Rep 2021
- High levels of ubidecarenone (oxidized CoQ10) delivered using a drug-lipid conjugate nanodispersion (BPM31510) differentially affect redox status and growth in malignant glioma versus non-tumor cells.
Sun J, Patel CB, Jang T, et al. · Sci Rep 2020
- CoQ10 selective miscibility and penetration into lipid monolayers with lower lateral packing density.
Garg S, Swaminathan V, Dhavala S, et al. · Biochim Biophys Acta Biomembr 2017
Also in development for Glioblastoma
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- L19TNFL19IL2, OnfekafuspPhase 310 trials
Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III
- VebreltinibPLB1001Phase 36 trials
Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, Glioblastoma, Non-Small Cell Lung Cancer
- VRT106Phase 33 trials
Guangzhou Virotech Pharmaceutical Co., Ltd. · Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma, HCC
- INO-9012Phase 24 trials
Geneos Therapeutics · HCC, Glioblastoma, Urothelial Carcinoma
- AL58805Phase 22 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- AzeliragonPhase 22 trials
Cantex Pharmaceuticals · Glioblastoma
- INO-5401Phase 22 trials
Inovio Pharmaceuticals · Glioblastoma, Urothelial Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.